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Abstract 
In APS vascular patients, thrombotic recurrences are more frequent than in non-APS thrombotic patients. 
To better define this clinical setting, a systematic review of the literature after 1999 was performed: 8 
cohort studies (including the recent APS Piedmont Cohort) and 6 intervention studies were selected and 
evaluated. Thrombotic recurrences, bleeding events, therapeutic strategies, antiphospholipid (aPL) profile, 
inherited and acquired risk factors (when present) were calculated and compared. Emerging risk factors for 
thrombotic recurrences include withdrawal of oral anticoagulant therapy (OAT), high intensity OAT (INR 
range 3–4), aPL profile (triple positivity, Miyakis types 1 and 2a profiles) and association with inherited or 
acquired pro-thrombotic risk factors. Moreover, there are evidences that high risk (mainly for aPL profile) 
APS vascular patients have a high recurrence rate in spite of correct OAT treatment. Clinical trials in this 
clinical setting are needed. 
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1. Introduction 
The antiphospholipid syndrome (APS) is a systemic, acquired, immuno-mediated syndrome, characterized 
by thrombotic events (venous, arterial or of the microcirculation) and/or by pregnancy morbidities and the 
persistent presence of circulating antiphospholipid antibodies. The clinical presentation of the syndrome 
may be “isolated” (idiopathic), or associated with other autoimmune diseases. Since Feinstein and 
Rapaport [1] used the term “lupus anticoagulant” for the first time in 1972, classification criteria for 
clinical and laboratory diagnosis have been proposed twice: i.e. Wilson et al. [2], in 1999 (the so-called 
“Sapporo” criteria), and the current ones, in 2006, by Miyakis et al. [3], (the “Sydney” criteria). These 
classification criteria have been formulated to allow a well-defined and shared picture of the syndrome. An 
in-depth review of APS classification criteria and therapeutic strategies, was recently published by Ruiz-
Irastorza et al. [4]. 
A “seronegative” form of the syndrome has been described and recently revised [5]; management of 
these patients is still unclear. 
Sydney classification criteria define the clinical characteristics of thrombotic (and obstetrical) events. Unlike 
the Sapporo criteria, superficial thrombophlebitis and TIAs have been excluded, as having all non-
objectively or histologically documented events. Indeed, other clinical manifestations such as aPL positive 
thrombocytopenia, livedo reticularis and migraine, which are often associated to the syndrome [6] and [7], 
are actually considered non-criteria manifestations, and are followed separately. Laboratory diagnosis is 
now more standardized both for the LA test and for the cut-off values for aCL, and furthermore the anti-
beta2glycoprotein I assay has been added. The time between the first test and the confirmation test has 
gone from 8 weeks to 12 weeks and the lag time between clinical symptoms (index event) and first positive 
test must not be more than 5 years. The syndrome is considered present if at least one of the tests (LA, aCL 
or anti-beta2glycoprotein I) is positive, and is later confirmed. 
An innovative aspect of the Sydney criteria consists in the fact that, for the first time, two adjunctive 
recommendations appear for the “researchers”. The first concerns the non-exclusion of APS patients 
with inherited or acquired pro-thrombotic conditions, classified as a) the presence or b) the absence of 
such risk factors. The second is a thrombotic risk stratification in different categories according to 
laboratory tests: type 1 if more than one positivity is present (in any combination), type 2a, 2b and 2c, 
respectively if LA, aCL or anti-beta2glycoprotein I alone are positive. These recommendations have not 
always been applied in studies concerning APS patients. 
There is strong evidence [8] concerning the fact that LA positivity alone correlates with higher thrombotic 
risk more than aCL or anti-beta2glycoprotein I positivity alone. Recently, the term “aPL profile” has 
replaced the term “category” of positivity, and good evidence has been published regarding the high 
predictive role of the “triple” positivity aPL profile, consisting in the simultaneous, persistent positivity 
for LA, aCL and anti-beta2glycoprotein I. APS patients with triple positivity, as well as asymptomatic 
patients with triple positivity are at higher risk of thrombosis and thrombotic recurrences [9] and [10]. 
Another very serious form of the syndrome, the so-called “catastrophics” APS, here is not considered, 
but has been recently revised [11]. 
This review only takes vascular APS into consideration, and in particular we focus on thrombotic 
recurrences. Nowadays the high frequency of thrombotic recurrences still represents a major clinical 
criticism and a yet unsolved therapeutic challenge. The aim of this paper was to evaluate the incidence of 
thrombotic recurrences, as well as the patients' risk factors, the aPL profile, and the bleeding events that 
have been reported in the literature, and to compare these data to the recent experience of the APS 
Piedmont Cohort [12]. 
We decided to systemically evaluate the literature reports after 1999; although the literature prior to 1999 
contains a wealth of important studies concerning APS, comparison with recent ones is not possible, since 
the former lack information on classification criteria of the syndrome. Fourteen studies were chosen and in-
depth evaluation was carried out. These studies were divided into two groups based on their 
methodological approach: cohort studies, usually retrospective or ambispective, which report the index 
event and recurrences, and intervention studies, retrospective or prospective, some of which were 
randomized, containing comparisons of thrombotic recurrences (and sometimes bleeding events) in 
patients treated with different therapeutic strategies. 
2. The APS Piedmont Consortium 
Is a group of volunteer physicians and biologists coming from different specialties, working in the Piedmont 
Region, which is in north-western Italy, an area of about 5 million people. The activity of the Consortium 
began in 2004. The aims of the Consortium are: 1) to diagnose, treat and follow up APS patients, and to 
record data at diagnosis in the Regional Registry for Rare Diseases (National Health Service) 2) to improve 
knowledge of the syndrome, and to share up-to-date diagnostic and therapeutic strategies; and 3) to 
discuss controversial clinical cases and to support clinical and laboratory research. The APS Piedmont 
Cohort study is an ambispective study that includes 217 consecutive APS patients, selected from a broader 
group of about 400 suspected cases [12]. Enrolled patients strictly met the ongoing clinical and laboratory 
classification criteria, and APS diagnosis was confirmed by a centralized board. All the diagnoses that were 
made before 2006 were revised afterwards on the basis of the Sydney criteria. Patients were anonymously 
entered into a database program (Excel). The characteristics that were reported include: sex, race, age, age 
at diagnosis, underlying autoimmune disease, if any, clinical manifestations at onset (defined as index 
event), aPL profile, inherited thrombophilia and cardiovascular risk factors. Ongoing therapy, before and 
after thrombosis diagnosis or recurrence was also recorded. The study was performed according to the 
principles of the Declaration of Helsinki and informed consent was signed by each patient at diagnosis, 
when they entered in the Interregional Registry of Rare Diseases — National Health Service. All thrombotic 
events were objectively documented and patients were treated according to current recommendations at 
the time of diagnosis [13], [14], [15], [16] and [17]. 
3. Cohort studies 
Eight cohort studies were chosen and evaluated (see Table 2). 
In 2002 Ruiz Irastorza et al. [18] studied 66 vascular APS patients who had been diagnosed according to the 
Sapporo criteria. It is an observational, retrospective cohort study in which all patients were treated with 
oral anticoagulant treatment (OAT), and INR target 3.5. The followup period lasted 12 months. The 
recurrence rate of thrombosis was 9.1% patients per year, while the recurrence of bleeding events was 6%. 
Patients spent 37% of their time in the INR range 3–4. The relatively short followup period and the low 
adherence to the target INR do not allow to get strong clinical messages. 
Turiel et al. [19] prospectively followed-up 56 patients with primary APS for 5 years. Sapporo criteria were 
used for diagnosis. The observed thrombosis recurrence rate was 5.4% patients per year. A high aCL level 
(> 40 GPL-U) was shown to be a risk factor for thrombotic recurrences. The treatment for venous 
thrombosis was OAT for 6 months, and 12 months in the case of pulmonary embolism, while therapy for 
arterial thrombosis consisted of either OAT or antiaggregants. In this study a relatively high incidence of 
thrombotic events may have been related to the early discontinuation of OAT (6 or 12 months). 
In the study by Forastiero et al. [20], 194 patients with persistent LA and/or aCL were followed up for a 
median of 45 months, regardless of whether they had had a previous thrombotic event or not. Half of the 
patients (n = 97) had had a thrombotic event at diagnosis (these were APS patients), and some patients 
were thrombocytopenic or had had a TIA, or had had obstetrical manifestations. Overall incidence of 
thrombosis was 5.6% patients per year. The calculated recurrence rate (28 patients out of 97 in 3.7 years) 
was 7.8% patients per year in APS patients. Ten out of 28 patients with recurrence had a venous 
thrombosis during OAT. An inherited pro-thrombotic condition was searched in 12 out of 21 patients with 
venous thrombosis, and 3 patients (25%) were positive (had protein C deficit and 2 had prothrombin 
G20210 mutations). The Authors found that the highest incidence of thrombosis in “LA patients” was 
related to the presence of both anti-beta2glycoprotein I and anti-prothrombin antibodies. Male gender and 
a previous thrombosis also independently correlated with thrombotic risk. 
Wittosky et al. [21] studied 36 APS patients diagnosed according to the Sapporo criteria and compared 
them to a matched cohort of 36 thrombotic patients in OAT without APS. It is a retrospective observational 
study. INR range was 2–3 for both groups. Recurrence rate was 9.6% patients per year in the APS group 
versus 0% in non-APS. Bleeding rates were 3.2% and 3.1%, respectively. In this small study, standard OAT 
treatment seems to be less effective in APS patients compared to thrombotic non-APS patients. 
In the study by Tarr et al., [22] 272 lupus patients were enrolled and followed-up for 5 years. Lupus patients 
were then divided into three groups, aPL negative, aPL positive and APS (84 patients who met the Sapporo 
criteria, afterwards revised according to Sydney). Recurrence rate in the APS patient group was 1.7% 
patients per year. Cut off values for aCL positivity was 22 GPL or 16 MPL, and 14.6 SGU/ml or 3 U/ml for 
IgM anti-beta2glycoprotein I. Only 21.2% of patients had LA positivity, while 10% had triple positivity. No 
trigger event was evident in any of the thrombotic events that were observed in the followup period. About 
half of the APS patients were treated with OAT (± ASA). In this paper, aPL profile, previous thrombosis and 
oral anticoagulant treatment were the risk factors influencing thrombotic risk. The rate of bleeding events 
was not reported. 
The paper by Cervera et al. [23] reports the results of the largest APS cohort ever studied. It is a 
prospective, multicenter study. Sapporo diagnostic classification criteria were used and the drop out rate 
was 15%. 16.6% of patients had a recurrent thrombotic event, with a calculated recurrence rate of 3.3% 
patients per year. OAT was used in 420 patients, but more than half of the recurrences presented during 
OAT. The bleeding rate was 1.5% patients per year. Important clinical considerations from this study are 
that in the “real world” a significant proportion (23%) of APS patients do not receive either OAT or 
antiaggregant treatment, and that many patients had recurrences in spite of OAT. On the other hand, 
serious or lethal bleeding complications were not negligible. Data concerning general cardiovascular risk 
factors or inherited thrombophilia are not available. 
The study by Pengo et al. [9] is an ambispective, multicenter study. Laboratory criteria for enrollment were 
confirmed triple positivity for aPL tests. This is the first study concerning “high risk” APS patients 
selected for aPL profile at diagnosis. The followup period was more than 5 years, and the recurrence rate 
was 5.2% patients per year, with the highest rate (12.2%) being observed in the first year. The recurrence 
rate was significantly higher in patients not on OAT. Furthermore, OAT was the only predictor of 
thrombotic events during the followup. Bleeding rate was 0.8% patients per year. The index event at 
diagnosis (arterial or venous) did not predict the site of recurrence. 
4. The APS Piedmont Cohort study 
It is an ambispective, multicenter study. Sydney classification criteria were used for diagnosis. One hundred 
seventy-seven patients were enrolled (the clinical characteristics of the cohort are summarized in Table 1). 
The qualifying event at diagnosis was VTE in 100 cases (57%) and arterial thrombosis in 77 cases (43%). 
Miyakis types 1 and 2a aPL profiles (compared to 2b and 2c) were very highly represented (96%) in our 
cohort. Twenty-six percent of our patients had “triple” aPL positivity. Thrombotic recurrences in the 
followup period were 54: 24% patients were under OAT, 28% on low dose aspirin, 46% were off therapy, 
and 2% were under OAT plus aspirin. The thrombotic recurrence rate was 6% patients per year. There were 
12 major bleeding events, eight of which occurred in patients on oral anticoagulants (1.6% patients per 
year). No differences in aPL profile were observed between patients with arterial and venous events. The 
same aPL profile (Miyakis types 1 and 2a) was observed in patients with or without recurrences. Diabetes 
(p < 0.01; OR 10) and thrombophilia (p < 0.0078; OR 4) were independent risk factors for recurrence. To our 
knowledge, this is the first study in which enrollment of consecutive APS patients was strictly performed 
according to the Sydney criteria, and in a well defined geographical area. Moreover, laboratories performed 
periodic external quality assessment (EQA), and clinical events and laboratory tests were evaluated by a 
central board. Generic cardiovascular risk factors and inherited thrombophilia were also evaluated, and 
both thrombotic recurrences and bleeding events were calculated. 
5. Intervention studies 
Six intervention studies have been selected and evaluated (see Table 3). 
The study by Crowther et al. [24] was a prospective, randomized one on APS patients enrolled according to 
the Sapporo criteria. Patients were assigned to two different intensities of anticoagulation groups: INR 2–3 
versus 3–4. Recurrence rate was 1.3% patients per year in standard and 3.2 in high intensity INR treatment. 
Bleeding rates were 2.2% and 3.6%, respectively. The Authors underline the fact that in the high intensity 
INR group, patients spent in the correct INR range only in 40% of the time. As for the WASP study, the small 
sample size and low adherence to target INR do not allow us to come to definitive conclusions. 
Giron-Gonzales et al. [25] followed-up 404 patients that were divided into two groups: 1) 226 patients with 
primary or secondary APS according to the Sapporo criteria; 2) 178 asymptomatic aPL carriers. A total of 
176 vascular APS patients were treated with OAT, range 2.5–3.5. Those in group 2 did not receive 
continuous treatment, but were given thromboprophylaxis in high risk periods. The follow-up period was 
3 years. Eighteen patients died within the first 3 months of follow-up. 
The recurrence rate was 0.5% patients per year in group 1. Recurrent thrombosis were related to 
insufficient anticoagulation. Bleeding was 0.6%. The high death rate and the low recurrence rate make this 
study poorly comparable to other literature reports. 
The APASS study [26] is a prospective, randomized study of stroke patients (not APS patients) who received 
either warfarin with INR range of 1.4–2.8, or aspirin of 325 mg/die. Recurrence rate was 13% patients per 
year under OAT and 11% under aspirin. Bleeding events are not reported. The Authors report observing no 
differences between the results of the two treatments, nor that aPL status predicted vascular occlusive 
events. There was a great deal of criticisms concerning the study design, and some comments are 
summarized in JAMA, June 2004 [27] by Cabral et al., Ruiz Irastorza et al., Wahl et al. In summary, the mean 
age of patients was high, no confirmation tests were performed, only 0.2% patients had elevated aCL levels, 
and many patients were aPL positive (41%), leading to doubts concerning the specificity of the test, and the 
INR therapeutic target range was unusual and lower than the standard, most often recommended 
one [2] and [3]. More recently, the risk of ischaemic stroke and of myocardial infarction, has been shown to 
be very high in young women with lupus anticoagulant, in the RATIO study [28]. 
Ames et al. [29] enrolled 67 patients with primary APS according to the Sapporo criteria, 24 patients with a 
mitral valve replacement and 89 patients with inherited thrombophilia. All patients were under OAT; the 
followup period was 3.3 years. All patients were randomized to two different intensity regimens of OAT: 2–
3 versus 3–4 INR ranges. APS patients had 4% recurrence per year in the standard and 10.5% in the high 
intensity OAT regimen. Bleeding rate was higher in the high intensity INR range i.e. 10.5% versus 0.6%. Only 
10% of APS patients spent their time in 3–4 INR range, while 84% were in 2–3 INR range. Even in this case, 
the small number of patients and the low adherence to the target INR do not allow us to come to any firm 
conclusions. 
The WAPS study [30] is a prospective, randomized study of APS patients. One hundred and nine patients 
were enrolled according to the Sapporo criteria and were randomized to different OAT intensity 
treatments: INR 2–3 versus 3–4.5. The Authors show that high intensity warfarin was not superior to 
standard treatment: recurrence rate was 1.6% patients per year for INR 2–3, and 3.1% for higher intensity 
OAT. Bleeding rates were 1.6% for standard INR and 1% for high intensity INR, respectively. The results do 
not appear so rational, and could, at least in part, be explained by the relatively small sample size. 
Furthermore adherence to the high intensity treatment was suboptimal. 
Okuma et al. [31] enrolled 20 APS stroke patients according to the Sydney criteria. They were randomized 
to receive aspirin 100 mg or aspirin 100 mg associated to OAT, with INR 2–3. The recurrence rate in the 
former group was 16.2% patients per year versus 2.5% in the latter group. This small study suggests that 
aspirin alone is less effective than OAT plus aspirin in the clinical subset of APS stroke patients. 
6. Conclusions and comments 
The recurrence rate of venous thromboembolism in the general population (non-APS patients) was quite 
well defined in 1996 by Prandoni et al. [32] who showed a 30% cumulative incidence of recurrence after 
8 years of followup (i.e. 3.75% patients per year, in subjects off therapy). Similar results were obtained by 
Hansson et al. in 2000 [33], who reported a recurrence rate of 20% at 6 years, i.e. 3.33% patients per year 
after OAT withdrawal. The WODIT study by Agnelli et al. [34] demonstrated that, regardless of the duration 
of OAT treatment, a “cluster” of recurrences occurs in the first months after OAT discontinuation. 
A direct comparison of the calculation of thrombotic (both venous and arterial) recurrence rates in studies 
concerning APS patients is quite difficult, because of the different classification criteria, laboratory cut off 
values, and the different therapeutic strategies [35]. However, an approximate thrombosis recurrence rate 
can be deduced from the above mentioned studies. If we rule out the studies with the shorter followup 
period (about 1 year) (see Table 2: 18,21) due to the higher recurrence rate in the first year, and a small 
study concerning only APS stroke patients (see Table 3: 30), resulting thrombotic recurrences range 
between 2 and 10% patients per year. It must be underlined that a great deal of these patients was under 
OAT, and the higher the INR intensity, the higher the recurrence rate. Thrombotic recurrences are generally 
higher (when calculated) in the first year of followup [9], [12], [18] and [21]. 
Moreover, if bleedings are difficult to calculate by an objective method, bleeding rates in APS studies were 
different and scattered with respect to the rates observed in the general population under OAT. In the 
ISCOAT study [36], the bleeding rate (for major bleedings) among the general population under OAT was 
about 1% patients per year. In the studies we analyzed, the annual bleeding rate ranges from 0.6 to 10%, 
but if more recent studies in which INR range was 2–3 are considered separately (see Table 2: 9,23,12; see 
Table 3: 29), bleedings drop from 0.8 to 1.6%, similar to those of the ISCOAT study. 
On the basis of the above mentioned studies, which include about two thousands patients as a whole, 
some conclusions may be drawn. First, the absence of OAT (or OAT under-treatment) is often a significant, 
independent (sometimes the only one) risk factor for thrombotic recurrence. In clinical practice, a missed 
APS diagnosis, or early OAT withdrawal, must be considered as the cause of thrombotic recurrences. 
Second, the possibility that a clinical subset of APS vascular exists, i.e., those who have recurrences despite 
correct OAT, must be seriously considered. This fact represents a treatment failure, and some studies have 
shown that this is not at all a rare event [9], [12] and [37]. In particular, this happens in higher risk patients 
for aPL profile (triple positivity, Miyakis types 1 and 2a) [38]. 
Thrombotic recurrence rates in all of the studies are always higher than bleeding rates with the exception 
of[24], and high intensity INR range is less effective in preventing thrombosis and gives a higher bleeding 
risk. Generic cardiovascular risk factors and inherited thrombophilia can also further increase thrombotic 
risk [12] and [20]. 
In conclusion, OAT with the standard 2–3 INR range can still be considered a good therapeutic strategy for 
non-high risk APS patients [39], [40], [41] and [42] suffering from their first venous thrombotic event. 
However, poor or no evidence is available for the optimal treatment of APS vascular patients with arterial 
thrombosis [43], of high risk patients (due to aPL profile or to other associated acquired or inherited risk 
factors) or of patients who have vascular recurrences despite appropriate therapy. Large prospective, 
randomized clinical trials are needed in these clinical settings. 
Take-home messages 
•APS vascular patients have thrombotic recurrences more frequently than non-APS thrombotic patients. 
This often occurs also if APS patients are under oral anticoagulant treatment. 
•To better define the subset of APS patients a higher risk for thrombotic recurrence is mandatory, but this 
is rarely performed, either in clinical trials, or in the “real world” clinical practice 
•Emerging risk factors for thrombotic recurrences are: the aPL “profile”, withdrawal of OAT, associated 
general risk factors and inherited thrombophilia 
•This subset of patients, at very high risk for clinical characteristics and laboratory diagnosis, would be to 
consider for a randomized, prospective trial, using a new therapeutic strategy. 
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